2023 Cancer and Blood Disorders Outcomes

By the Numbers

* "By the Numbers" data for January 1, 2022 - December 31, 2022, in line with the last U.S. News and World Report Survey

Arkansas Children’s Cancer & Blood Disorders team sees an average of 11,000 appointments yearly.
Provides cancer or blood disorders care to over 250 patients at any given time.
Performed 7 Chimeric Antigen Receptor (CAR) T-cell infusions
Performed 8 autologous and 8 allogeneic stem cell transplants, including with mis-matched donors

Awards and Achievements

Best Children's Hospitals - US News & World Report - Cancer

2023-2024 USNWR ranking
FACT accredited autologous and stem cell collection
Modern therapies, CAR-T and photopheresis
DA-approved gene therapy
Children’s Oncology Group (COG) member
Early Phase Clinical Trials Through POETIC, Beat Childhood Cancer and industry partnerships
Certified Chimeric Antigen Receptor (CAR) T-Cell Therapy Center
The THRIVE Clinic, a survivorship program, offers a multidisciplinary support team to coordinate visits and decrease disruption of newfound normalcy for up to 10 years post-treatment.
Becker’s list of 100 hospitals and health systems with great oncology programs | 2023

Cancer and Blood Disorders Service Chief

"I practice here because I know my patients will get the best care possible, with tremendous support from our entire team, with compassion, expertise and an emphasis on safety."

David Becton, M.D.
Pediatric hematologist/oncologist, Arkansas Children’s Hospital
Chief of pediatric hematology and oncology
Lawrence H. Schmieding Chair in pediatric hematology-oncology
Professor of pediatrics, University of Arkansas for Medical Sciences